Company Profiles

driven by the PitchBook Platform

Kolltan Pharmaceuticals

Description

Developer of monoclonal antibody drugs. The company is a clinical-stage enterprise focused on discovery and development of drug candidates targeting receptor tyrosine kinases (RTKs) that impact oncology and immunology. The company's most advanced product candidates include KTN3379, a monoclonal antibody drug candidate targeting ErbB3 (HER3), which is currently in clinical development for the potential treatment of different solid tumors, and KTN0158, a monoclonal antibody targeting KIT, which is in clinical evaluation for cancer and preclinical evaluation for mast cell diseases.

2007

Founded

M&A

Status

11-50

Employees

M&A

Latest Deal Type

$235M

Latest Deal Amount

$140M

Total Amount Raised

Description

Developer of monoclonal antibody drugs. The company is a clinical-stage enterprise focused on discovery and development of drug candidates targeting receptor tyrosine kinases (RTKs) that impact oncology and immunology. The company's most advanced product candidates include KTN3379, a monoclonal antibody drug candidate targeting ErbB3 (HER3), which is currently in clinical development for the potential treatment of different solid tumors, and KTN0158, a monoclonal antibody targeting KIT, which is in clinical evaluation for cancer and preclinical evaluation for mast cell diseases.

Website:

www.kolltan.com

Ownership Status

Acquired/Merged

Financing Status

Formerly VC-Backed

Primary Industry

Drug Discovery

Primary Office

300 George Street Suite 530 New Haven, CT 06511United States
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Kolltan Pharmaceuticals's full profile, request a free trial.

    Kolltan Pharmaceuticals Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Kolltan Pharmaceuticals Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Kolltan Pharmaceuticals Executive Team (8)

    NameTitleBoard
    Seat
    Contact
    Info
    Joseph Schlessinger Ph.DCo-Founder, Director and Chairman of Scientific Advisory Board
    Lisa KamenDirector, Clinical Operations
    Leigh FeigenbaumDirector, Regulatory & Clinical Affairs
    Colin CallaghanSenior Director, Product Development & Product Management
    Ronald Peck MDCo-Chief Medical Officer & Senior Vice President of Clinical Development
    Joseph Schlessinger Ph.D Co-Founder, Director and Chairman of Scientific Advisory Board
    Lisa Kamen Director, Clinical Operations
    Leigh Feigenbaum Director, Regulatory & Clinical Affairs
    Colin Callaghan Senior Director, Product Development & Product Management
    Ronald Peck MD Co-Chief Medical Officer & Senior Vice President of Clinical Development

    Kolltan Pharmaceuticals Board Members (7)

    NameRepresentingRoleSinceContact
    Info
    Arthur Altschul Jr.SelfCo-Founder and Chairman000 0000
    Daniel Vlock MDSelfDirector000 0000
    Frank KarbeKolltan PharmaceuticalsBoard Member000 0000
    Jonathan Soderstrom Ph.DSelfDirector000 0000
    Paul MedeirosSelfDirector000 0000
    Arthur Altschul Jr. Co-Founder and Chairman Self
    Daniel Vlock MD Director Self
    Frank Karbe Board Member Kolltan Pharmaceuticals
    Jonathan Soderstrom Ph.D Director Self
    Paul Medeiros Director Self
    Request full access to PitchBook